Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several headwinds, including the fact that it didn't meet investors' sky-high ...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...
LY-3971297 is under clinical development by Eli Lilly and Co and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) ...
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, ...
2025 Healthcare & Pharmaceuticalscategory US FDA approves expanded use of Lilly's bowel disease drug January 16, 2025 Healthcare & Pharmaceuticalscategory US bans use of Red No.3 dye in food ...